Drug Profile
EnAd EpCAM BiTE
Alternative Names: Oncolytic adenovirus expressing BiTELatest Information Update: 09 Jan 2023
Price :
$50
*
At a glance
- Originator University of Oxford
- Developer Akamis Bio; University of Oxford
- Class Antineoplastics; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer